Cancer Research Nottingham

Cancer Research Nottingham

The University of Nottingham, in partnership with the NHS (Queens Medical Centre, Nottingham City Hospital and the Royal Derby Hospital), is committed to promoting research into the detection, causes and treatment of cancer. 

Our scientists, clinicians and healthcare professionals work together on a broad range of research themes, aiming to enhance our understanding of cancer biology and ensure translation of our findings into new, safer treatments and improved patient care.

Study with us

We offer undergraduate and postraduate opportunities to study cancer. Vist our study with us page to find out more.



Contact us

  • Tel: +44 (0)115 82 31135
  • For website queries, contact Loretta Waddon 





Cancer RPA Event 2016

Some of the staff who attended the recent Cancer Research Priority Area event facilitated by Dr Maeve Fitzpatrick and Know Innovation held at the Orchard Hotel, University of Nottingham Campus.

Internal Research Funding Scheme

The competitive internal awards programme to support scientific and clinical brain tumour research projects at the University is now open.

CRN Symposium 2016

The 2016 Cancer Research Nottingham (CRN) Symposium program featured industrial, medical and scientific sessions of interest to all members of the Cancer Research Priority Area at University of Nottingham.

CRN Symposium 2014

The CRN Annual Symposium (January 15th 2014) showcased some of the diverse activities in cancer research taking place across the University and our partner institutions.




2020 Cancer Research Nottingham (CRN) Virtual Symposium

10-11th November 2020


An internal ribosome entry site in the 5' untranslated region of epidermal growth factor receptor allows hypoxic expression. Webb TE, Hughes A, Smalley DS, Spriggs KA. (2015) Oncogenesis Jan 26;4:e134.

FKBPL: a marker of good prognosis in breast cancer. Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirstrom K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T. Oncotarget 2015;6(14):12209-23.

The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape. Modelska A, Turro E, Russell R, Beaton J, Sbarrato T, Spriggs K, Miller J, Gräf S, Provenzano E, Blows F, Pharoah P, Caldas C, Le Quesne J. (2015) Cell Death Dis. Jan 22;6:e1603.